Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma
Clinical trial NCT02594163 · TERMINATED
Trial details
- NCT number
- NCT02594163
- Sponsor
- Seagen Inc.
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-10-01
- Primary completion
- 2017-09-01
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.